Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853027 | 1.00 | TTR (0.44) | TTRMCL1MEN1POLBKMT2A | |
| SCHEMBL6852840 | 0.76 | CYP1A2 (0.59) | TTRMCL1CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL7163064 | 0.76 | CYP1A2 (0.59) | TTRMCL1CYP1A2CYP2C9CYP3A4 | |
| SCHEMBL6023835 | 0.74 | PKM (0.55) | TTRMCL1MEN1POLBKMT2A | |
| SCHEMBL6023839 | 0.74 | PKM (0.55) | TTRMCL1MEN1POLBKMT2A | |
| SCHEMBL7160153 | 0.74 | GSR (0.50) | TTRMCL1LCKCYP1A2CYP2C9 | |
| SCHEMBL7160152 | 0.74 | GSR (0.50) | TTRMCL1LCKCYP1A2CYP2C9 | |
| SCHEMBL30186421 | 0.71 | TTR (0.54) | TTRCYP1A2CYP2C9CYP3A4 | |
| SCHEMBL2390177 | 0.66 | CYP3A4 (0.64) | TTRCYP3A4PTGS2 | |
| SCHEMBL5693337 | 0.66 | TTR (0.57) | TTRMCL1KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777447-B2 | ANTIINFLAMMATORY AGENTS, BACTERICIDES, OXIDATION RESISTANCE, ANTICANCER AGENTS | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2004-08-17 | — | — | US | claimed |
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2003-05-15 | — | — | US | claimed |
| US-6777447-B2 | ANTIINFLAMMATORY AGENTS, BACTERICIDES, OXIDATION RESISTANCE, ANTICANCER AGENTS | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2004-08-17 | — | — | US | disclosed |
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GADJAH MADA, FACULTY OF PHARMACY, UNIVERSITY OF, THE (ID) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092772-A1 | Derivatives of benzylidene cyclohexanone, benzylidene cyclopentanone, and benzylidene acetone, and therapeutic uses thereof | GSTK1, GSTP1, CAT | TTR 4184/4885MCL1 2648/4885MEN1 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.